Med Tech-related technology assessments and clinical guidelines from NICE in July 2022

10

Aug 2022

In July 2022, NICE published two Interventional Procedures Guidance (IPG):

IPG is developed for most of the novel interventional procedures entering the English market. The program focuses solely on clinical evidence. Recommendations may vary from "for research only" to "for use with standard arrangements for clinical governance, consent, and audit." Recommendations are not binding, although they are followed by providers and commissioners.

NICE made recommendations depending on the clinical indications::

  • For people with severe and symptomatic tricuspid regurgitation, evidence on the efficacy of both transcatheter tricuspid valve annuloplasty and leaflet repair is limited in quantity and quality. Evidence on its safety shows there are serious but well-recognized complications. Therefore, these procedures should only be used with special arrangements for clinical governance, consent, and audit or research;
  • For people with mild or moderate tricuspid regurgitation, evidence on the safety and efficacy of both transcatheter tricuspid valve annuloplasty and leaflet repair is inadequate in quantity and quality. Therefore, these procedures should only be used in the context of research.

The Diagnostic Guidance (DG) program focuses on evaluating innovative medical diagnostic technologies to ensure that the NHS can adopt clinically and cost-effective technologies rapidly and consistently.

In July 2022, NICE published one new DG on PLGF-based testing to help diagnose suspected preterm pre-eclampsia. NICE recommended the following placental growth factor (PLGF)-based tests, used with standard clinical assessment, to help decide on care (to help rule in or rule out pre-eclampsia) for people with suspected preterm (between 20 weeks and 36 weeks and six days of pregnancy) pre‑eclampsia:

  • DELFIA Xpress PLGF 1-2-3;
  • DELFIA Xpress sFlt-1/PLGF 1-2-3 ratio;
  • Elecsys immunoassay sFlt-1/PLGF ratio;
  • Triage PLGF Test.

BRAHMS sFIT-1 Kryptor/BRAHMS PLGF plus Kryptor PE ratio is not recommended for routine use in the NHS. Further research is needed to show the accuracy of this test when using specified thresholds. NICE concluded that PLGF-based testing might particularly benefit groups at higher risk of severe adverse pregnancy outcomes, such as people from African, Caribbean, and Asian family backgrounds.

The MedTech Innovation Briefings (MIBs) is the advice program of NICE for innovative technologies. It provides an overview of clinical effectiveness, safety, and cost. It does not offer formal guidance, and it, therefore, does not provide any recommendations. The four new MIBs published in July 2022 are:

Five clinical guidelines were updated in July 2022:

See the full details for guidance here and for MIBs here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news

23

Sep 2022

On September 5, 2022, it was announced that the Interterritorial Council for the Spanish National Health System (CISNS) approved the distribution of funds to the Autonomous Communities for the fight against cancer. The aim is to boost the screening programs for colorectal and cervical cancer.

Read more

22

Sep 2022

On September 01, 2022, NHS England published an update of the Specialized Services Policy Pipeline (as of August 24, 2022). Two new MedTech-related Clinical Commissioning Policies were added to the work program (transcatheter edge-to-edge repair of the mitral valve, pectus surgery for really severe pectus), and no new policies were published. The status of ongoing policies was updated as well.

Read more

16

Sep 2022

In August 2022, the National Institute for Health and Care Research (NIHR) in England released two MedTech-related reports in its Health Technology Assessment (HTA) Journal, which concerned the treatment of urodynamic stress incontinence after prostate surgery and closure techniques after surgery for colorectal cancer. HTA Journal publishes research reports on the effectiveness, costs, and broader impact of health technologies for those who use, manage, and provide care in the NHS and informs National Institute for Health and Care Excellence (NICE) guidance.

Read more

15

Sep 2022

On August 25, 2022, the Norwegian Directorate of Health announced the launch of the National screening program for colorectal cancer (Bowel screening program - Tarmscreeningprogrammet). All 55-year-old men and women will be included in the program and offered a test to identify invisible blood in the stool (fecal immunochemical test, FIT) every two years until the age of 65. Colonoscopy will be offered in case of positive FIT.

Read more

14

Sep 2022

The French National Authority for Health (HAS) released new recommendations about transitional coverage of medical devices from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in August 2022. One opinion was published regarding the cardiac resynchronization system WISE CRT-SYSTEM by EBR System.

Read more